Immunohistochemistry (IHC) for HER2, programmed death ligand 1 (PD-L1), and mismatch repair (MMR) proteins is extensively used to analyses tumor characteristics that are critical for treatment decisions [15]. Here, ERBB2 is linked to neoplasm.